Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2017

Open Access 01-12-2017 | Research article

Changes over time in prescription practices of pain medications in Switzerland between 2006 and 2013: an analysis of insurance claims

Authors: Maria M. Wertli, Oliver Reich, Andri Signorell, Jakob M. Burgstaller, Johann Steurer, Ulrike Held

Published in: BMC Health Services Research | Issue 1/2017

Login to get access

Abstract

Background

In Europe, scant information is available about prescription practices for pain medications. The aim of this research was to assess changes in prescription rates of non-opioid, weak opioid, and strong opioid medications between 2006 and 2013 in the Swiss population.

Methods

Using insurance claims data covering one-sixth of the Swiss population, we analyzed the numbers of reimbursed pain medications, the number of reimbursements per persons, and the cumulative dose in milligrams. For opioids, the morphine equivalent dose and treatment days were calculated. Data were extrapolated to the dose per day per 100’000 population stratified by age, gender, and canton.

Results

In total, 4’746’942 paracetamol, 2’156’620 NSAIDs or Coxibs, 931’129 metamizole, 1’322’272 weak opioid, and 807’835 strong opioid claims were analyzed. Between 2006 and 2013, the increase in claims per 100’000 persons was 32% for paracetamol, 242% for metamizole, 107% for NSAIDS, 86% for Coxibs, 13% for weak opioids, and 121% for strong opioids. For strong opioids the total MED in mg /100’000 increased by 117%, the treatment days /100’000 by 101%. For strong opioids, fentanyl was most frequently used (increase between 2006 and 2013 by 91% for MED/100’000 persons and 94% treatment days / 100’000) followed by buprenorphine and oxycodone. The highest proportional increase in MED / 100’000 was observed for methadone (+1414%) and oxycodone (+313%). Marked geographical variation was detected in the use of metamizole, paracetamole, and strong opioids in different cantons.

Conclusion

The analysis of insurance claims data provides evidence that the prescription rates for pain medications increased in Switzerland within the last ten years, in particular for metamizole and strong opioids. Furthermore, the prescription rates for metamizole, paracetamol, and strong opioids varied substantially between different cantons in Switzerland.
Appendix
Available only for authorised users
Literature
1.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–96.CrossRefPubMed
2.
Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, La Vecchia C. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71.CrossRefPubMed
3.
WHO Expert Committee on Cancer Pain Relief and Active Supportive Care. Cancer pain relief and palliative care: report of a WHO expert committee. Genève: Organisation mondiale de la Santé; 1990. p. 84.
4.
World Health Organization. Traitement de la douleur cancéreuse: complétée par une analyse des problèmes liés à la mise à disposition des opioïdes. 2nd ed. Genève: Organisation mondiale de la Santé; 1997. p. 57–68.
5.
Theiler B, Wyrsch B. Rationale Schmerztherapie – oder doch nicht? Schweiz Med Forum. 2012;12(34):645–51.
6.
Manchikanti L, Abdi S, Atluri S, Balog C, Benyamin R, Boswell M, Brown K, Bruel B, Bryce D, Burks P, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment. Pain Physician. 2012;15(3 Suppl):S1–S65.PubMed
7.
Furlan A, Sandoval J, Mailis Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. Can Med Assoc J. 2006;174(11):1589–94.CrossRef
8.
Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(1–2):172–9.CrossRefPubMed
9.
Hojsted J, Kurita GP, Kendall S, Lundorff L, de Mattos Pimenta CA, Sjogren P. Non-Analgesic Effects Of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update. Curr Pharm Des. 2012;18(37):6116–22.
10.
Manchikanti L, Helm S, Fellows B, Janata J, Pampati V, Grider J, Boswell M. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38.PubMed
11.
12.
Manchikanti L, Atluri S, Hansen H, Benyamin RM, Falco FJ, Helm Ii S, Kaye AD, Hirsch JA. Opioids in chronic noncancer pain: have we reached a boiling point yet? Pain Physician. 2014;17(1):E1–E10.PubMed
13.
Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.CrossRefPubMed
14.
Shah NG, Lathrop SL, Reichard RR, Landen MG. Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. Addiction. 2008;103(1):126–36.CrossRefPubMed
15.
Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618–27.CrossRefPubMed
16.
Dunn K, Saunders K, Rutter C, Banta Green C, Merrill J, Sullivan M, Weisner C, Silverberg M, Campbell C, Psaty B, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92.CrossRefPubMedPubMedCentral
17.
Jena AB, Goldman D, Weaver L, Karaca-Mandic P. Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims. BMJ. 2014;348:g1393.CrossRefPubMedPubMedCentral
18.
Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995–2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19(1):59–66.CrossRefPubMed
19.
20.
Biller-Andorno N, Zeltner T. Individual Responsibility and Community Solidarity — The Swiss Health Care System. N Engl J Med. 2015;373(23):2193–7.CrossRefPubMed
21.
Korff MV, Saunders K, Thomas Ray G, Boudreau D, Campbell C, Merrill J, Sullivan MD, Rutter CM, Silverberg MJ, Banta-Green C, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–7.CrossRefPubMed
22.
23.
R Core Team. R: A language and environment for statistical computing. In: R Core Team, editor. R Foundation for Statistical Computing. Vienna: R Core Team; 2015.
24.
Schubert I, Ihle P, Sabatowski R. Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Deutsches Ärzteblatt international. 2013;110(4):45–51.
25.
Ekholm O, Kurita GP, Højsted J, Juel K, Sjøgren P. Chronic pain, opioid prescriptions, and mortality in Denmark: A population-based cohort study. PAIN®. 2014;155(12):2486–90.CrossRef
26.
Hoffmann F, Meinecke P, Freitag MH, Glaeske G, Schulze J, Schmiemann G. Who gets dipyrone (metamizole) in Germany? Prescribing by age, sex and region. J Clin Pharm Ther. 2015;40(3):285–8.CrossRefPubMed
27.
Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657–65.CrossRefPubMed
28.
29.
Kotter T, da Costa BR, Fassler M, Blozik E, Linde K, Juni P, Reichenbach S, Scherer M. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0122918.CrossRefPubMedPubMedCentral
30.
Bosnjak S, Maurer MA, Ryan KM, Leon MX, Madiye G. Improving the availability and accessibility of opioids for the treatment of pain: the International Pain Policy Fellowship. Support Care Cancer. 2011;19(8):1239–47.CrossRefPubMed
31.
32.
Wertli MM, Steurer J. In Process Citation. Praxis (Bern 1994). 2015;104(11):541–2.CrossRef
33.
Hess B, Toniolo M. Stellenwert und Einsatz von Opioiden in der Therapie chronischer Schmerzen in Schweizer Arztpraxen – eine nationale Umfrage. PRAXIS. 2015;104(11):557–63.CrossRefPubMed
34.
Breivik H, Stubhaug A. Burden of disease is often aggravated by opioid treatment of chronic pain patients: Etiology and prevention. PAIN®. 2014;155(12):2441–3.CrossRef
35.
Hess B, Toniolo M. Relevance and Application of Opioids in the Treatment of Chronic Pain in Switzerland - a National Survey. PRAXIS. 2015;104(11):557–63.CrossRefPubMed
36.
Hirsch A, Proescholdbell SK, Bronson W, Dasgupta N. Prescription histories and dose strengths associated with overdose deaths. Pain Med. 2014;15(7):1187–95.CrossRefPubMed
37.
Mounteney J, Giraudon I, Denissov G, Griffiths P. Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015;26(7):626–31.CrossRefPubMed
38.
Lapeyre-Mestre M, Dupui M. Drug abuse monitoring: which pharmacoepidemiological resources at the European level? Therapie. 2015;70(2):147–65.CrossRefPubMed
39.
Heyerdahl F, Hovda KE, Giraudon I, Yates C, Dines AM, Sedefov R, Wood DM, Dargan PI. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol. 2014;52(10):1005–12.CrossRef
40.
van Amsterdam J, van den Brink W. The Misuse of Prescription Opioids: A Threat for Europe? Curr Drug Abuse Rev. 2015;8(1):3–14.CrossRefPubMed
Metadata
Title
Changes over time in prescription practices of pain medications in Switzerland between 2006 and 2013: an analysis of insurance claims
Authors
Maria M. Wertli
Oliver Reich
Andri Signorell
Jakob M. Burgstaller
Johann Steurer
Ulrike Held
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2017
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-017-2086-6

Other articles of this Issue 1/2017

BMC Health Services Research 1/2017 Go to the issue

Research article

Mental disorders and the use of primary health care services among homeless shelter users in the Helsinki metropolitan area, Finland

Research article

Informing the implementation of evidence-informed decision making interventions using a social network analysis perspective; a mixed-methods study

Research article

Pre/post evaluation of a pilot prevention with positives training program for healthcare providers in North West Province, Republic of South Africa

Research article

“We and the nurses are now working with one voice”: How community leaders and health committee members describe their role in Sierra Leone’s Ebola response

Research article

Acceptance and attitudes of healthcare staff towards the introduction of clinical pharmacy service: a descriptive cross-sectional study from a tertiary care hospital in Sri Lanka

Research article

Fostering development of nursing practices to support integrated care when implementing integrated care pathways: what levers to use?